IL17A and psoriasis: Consistent with the increased Th17 cell percentage, rHMGB1 treatment resulted in a dose‐dependent promotional effect on IL‐17A mRNA and protein expression levels in psoriasis patients' PBMCs (F = 83.94 and F = 36.13, both p < .001, Figures 5A and 6A).